Top

Open Access 04-01-2025 | Myocardial Infarction | Research

Novel Selective Cardiac Myosin-Targeted Inhibitors Alleviate Myocardial Ischaemia–Reperfusion Injury

Authors: Nur Liyana Mohammed Yusof, Derek M. Yellon, Sean M. Davidson

Published in: Cardiovascular Drugs and Therapy

Abstract

Purpose

Reperfusion of the ischaemic heart is essential to limit myocardial infarction. However, reperfusion can cause cardiomyocyte hypercontracture. Recently, cardiac myosin-targeted inhibitors (CMIs), such as Mavacamten (MYK-461) and Aficamten (CK-274), have been developed to treat patients with cardiac hypercontractility. These CMIs are well tolerated and safe in clinical trials. We hypothesised that, by limiting hypercontraction, CMIs may reduce hypercontracture and protect hearts in the setting of ischaemia and reperfusion (IR).

Methods

We investigated the ability of MYK-461 and CK-274 to inhibit hypercontracture of adult rat cardiomyocytes (ARVC) in vitro following ATP depletion. A suitable dose of CMIs for subsequent in vivo IR studies was identified using cardiac echocardiography of healthy male Sprague Dawley rats. Rats were anaesthetized and subject to coronary artery ligation for 30 min followed by 2 h of reperfusion. Prior to reperfusion, CMI or vehicle was administered intraperitoneally. Ischaemic preconditioning (IPC) was used as a positive control group. Infarct size was assessed by tetrazolium chloride staining and extent of hypercontracture was assessed by histological staining.

Results

Treatment with CMIs inhibited ARVC hypercontracture in vitro. MYK-461 (2 mg/kg) and CK-274 (0.5 mg/kg to 2 mg/kg) significantly reduced infarct size vs. vehicle. IR caused extensive contraction band necrosis, which was reduced significantly by IPC but not by CMIs, likely due to assay limitations. GDC-0326, an inhibitor of PI3Kα, abrogated CK-274-mediated protection following IR injury. GDC-0326 reduced phosphorylation of AKT when administered together with CK-274.

Conclusion

This study identifies CMIs as novel cardioprotective agents in the setting of IR injury.

Available only for authorised users

Stone GW, Selker HP, Thiele H, et al. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. J Am Coll Cardiol. 2016;67(14):1674–83. https://doi.org/10.1016/j.jacc.2016.01.069.CrossRefPubMed

Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56(5):786–94. https://doi.org/10.1161/01.cir.56.5.786.CrossRefPubMed

Ovize M, Baxter G, Di Lisa F, Working Group of Cellular Biology of Heart of European Society of C, et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2010;87(3):406–23. https://doi.org/10.1093/cvr/cvq129.CrossRefPubMed

Ruiz-Meana M, Abellan A, Miro-Casas E, Garcia-Dorado D. Opening of mitochondrial permeability transition pore induces hypercontracture in Ca2+ overloaded cardiac myocytes. Basic Res Cardiol. 2007;102(6):542–52. https://doi.org/10.1007/s00395-007-0675-y.CrossRefPubMed

Rodriguez-Sinovas A, Abdallah Y, Piper HM, Garcia-Dorado D. Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction. Heart Fail Rev. 2007;12(3–4):207–16. https://doi.org/10.1007/s10741-007-9039-9.CrossRefPubMed

Bell RM, Botker HE, Carr RD, et al. 9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Basic Res Cardiol. 2016;111(4):41. https://doi.org/10.1007/s00395-016-0558-1.CrossRefPubMedPubMedCentral

Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121–35. https://doi.org/10.1056/NEJMra071667.CrossRefPubMed

Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res. 1998;38(2):291–300. https://doi.org/10.1016/s0008-6363(98)00033-9.CrossRefPubMed

Garcia-Dorado D, Theroux P, Duran JM, et al. Selective inhibition of the contractile apparatus. A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion. Circulation. 1992;85(3):1160–74. https://doi.org/10.1161/01.cir.85.3.1160.CrossRefPubMed

10.

Verrecchia F, Herve JC. Reversible blockade of gap junctional communication by 2,3-butanedione monoxime in rat cardiac myocytes. Am J Physiol. 1997;272(3 Pt 1):C875–85. https://doi.org/10.1152/ajpcell.1997.272.3.C875.CrossRefPubMed

11.

Inserte J, Barba I, Hernando V, et al. Effect of acidic reperfusion on prolongation of intracellular acidosis and myocardial salvage. Cardiovasc Res. 2008;77(4):782–90. https://doi.org/10.1093/cvr/cvm082.CrossRefPubMed

12.

Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10293):2467–75. https://doi.org/10.1016/S0140-6736(21)00763-7.CrossRefPubMed

13.

Maron MS, Masri A, Choudhury L, et al. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2023;81(1):34–45. https://doi.org/10.1016/j.jacc.2022.10.020.CrossRefPubMed

14.

Ho CY, Olivotto I, Jacoby D, et al. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. Circ Heart Fail. 2020;13(6):e006853. https://doi.org/10.1161/CIRCHEARTFAILURE.120.006853.CrossRefPubMed

15.

Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351(6273):617–21. https://doi.org/10.1126/science.aad3456.CrossRefPubMedPubMedCentral

16.

Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759–69. https://doi.org/10.1016/S0140-6736(20)31792-X.CrossRefPubMed

17.

Argiro A, Zampieri M, Berteotti M, et al. Emerging Medical Treatment for Hypertrophic Cardiomyopathy. J Clin Med. 2021;10(5):951. https://doi.org/10.3390/jcm10050951.CrossRefPubMedPubMedCentral

18.

Chuang C, Collibee S, Ashcraft L, et al. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J Med Chem. 2021;64(19):14142–52. https://doi.org/10.1021/acs.jmedchem.1c01290.CrossRefPubMed

19.

Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288(2):H971–6. https://doi.org/10.1152/ajpheart.00374.2004.CrossRefPubMed

20.

Gong GQ, Bilanges B, Allsop B, et al. A small-molecule PI3Kalpha activator for cardioprotection and neuroregeneration. Nature. 2023;618(7963):159–68. https://doi.org/10.1038/s41586-023-05972-2.CrossRefPubMedPubMedCentral

21.

Yellon DM, Beikoghli Kalkhoran S, Davidson SM. The RISK pathway leading to mitochondria and cardioprotection: how everything started. Basic Res Cardiol. 2023;118(1):22. https://doi.org/10.1007/s00395-023-00992-5.CrossRefPubMedPubMedCentral

22.

Rossello X, Riquelme JA, Davidson SM, Yellon DM. Role of PI3K in myocardial ischaemic preconditioning: mapping pro-survival cascades at the trigger phase and at reperfusion. J Cell Mol Med. 2018;22(2):926–35. https://doi.org/10.1111/jcmm.13394.CrossRefPubMed

23.

Rossello X, Riquelme JA, He Z, et al. The role of PI3Kalpha isoform in cardioprotection. Basic Res Cardiol. 2017;112(6):66. https://doi.org/10.1007/s00395-017-0657-7.CrossRefPubMedPubMedCentral

24.

Hausenloy DJ, Garcia-Dorado D, Botker HE, et al. Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res. 2017;113(6):564–85. https://doi.org/10.1093/cvr/cvx049.CrossRefPubMed

25.

Hausenloy DJ, Yellon DM. Combination Therapy to Target Reperfusion Injury After ST-Segment-Elevation Myocardial Infarction: A More Effective Approach to Cardioprotection. Circulation. 2017;136(10):904–6. https://doi.org/10.1161/CIRCULATIONAHA.117.029859.CrossRefPubMed

26.

Davidson SM, Ferdinandy P, Andreadou I, et al. Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(1):89–99. https://doi.org/10.1016/j.jacc.2018.09.086.CrossRefPubMed

27.

Shah M, He Z, Rauf A, et al. Extracellular histones are a target in myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2022;118(4):1115–25. https://doi.org/10.1093/cvr/cvab139.CrossRefPubMed

28.

Botker HE, Hausenloy D, Andreadou I, et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol. 2018;113(5):39. https://doi.org/10.1007/s00395-018-0696-8.CrossRefPubMedPubMedCentral

29.

Ganote CE, Armstrong SC. Effects of CCCP-induced mitochondrial uncoupling and cyclosporin A on cell volume, cell injury and preconditioning protection of isolated rabbit cardiomyocytes. J Mol Cell Cardiol. 2003;35(7):749–59. https://doi.org/10.1016/s0022-2828(03)00114-7.CrossRefPubMed

30.

Smeele KM, Southworth R, Wu R, et al. Disruption of hexokinase II-mitochondrial binding blocks ischemic preconditioning and causes rapid cardiac necrosis. Circ Res. 2011;108(10):1165–9. https://doi.org/10.1161/CIRCRESAHA.111.244962.CrossRefPubMed

31.

Haworth RA, Hunter DR, Berkoff HA. Contracture in isolated adult rat heart cells. Role of Ca2+, ATP, and compartmentation. Circ Res. 1981;49(5):1119–28. https://doi.org/10.1161/01.res.49.5.1119.CrossRefPubMed

32.

Bromage DI, Taferner S, He Z, Ziff OJ, Yellon DM, Davidson SM. Stromal cell-derived factor-1alpha signals via the endothelium to protect the heart against ischaemia-reperfusion injury. J Mol Cell Cardiol. 2019;128:187–97. https://doi.org/10.1016/j.yjmcc.2019.02.002.CrossRefPubMedPubMedCentral

33.

Shah B, Kunal S, Bansal A, et al. Heart rate variability as a marker of cardiovascular dysautonomia in post-COVID-19 syndrome using artificial intelligence. Indian Pacing Electrophysiol J. 2022;22(2):70–6. https://doi.org/10.1016/j.ipej.2022.01.004.CrossRefPubMedPubMedCentral

34.

Basalay M, Downey JM, Davidson S, Yellon D. The Infarct-Limiting Effect of Remote Ischemic Conditioning in Rats Is Not Affected by Aspirin. Cardiovasc Drugs Ther. 2023;1–5.

35.

Hartman JJ, Hwee DT, Robert-Paganin J, et al. Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res. 2024;3(8):1003–16. https://doi.org/10.1038/s44161-024-00505-0.CrossRefPubMedPubMedCentral

36.

Grillo MP, Erve JCL, Dick R, et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica. 2019;49(6):718–33. https://doi.org/10.1080/00498254.2018.1495856.CrossRefPubMed

37.

Ather S, Chan W, Chillar A, et al. Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: a complex relationship. Am Heart J. 2011;161(3):567–73. https://doi.org/10.1016/j.ahj.2010.12.009.CrossRefPubMedPubMedCentral

38.

Hausenloy DJ, Barrabes JA, Botker HE, et al. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol. 2016;111(6):70. https://doi.org/10.1007/s00395-016-0588-8.CrossRefPubMedPubMedCentral

39.

Hausenloy DJ, Iliodromitis EK, Andreadou I, et al. Investigating the signal transduction pathways underlying remote ischemic conditioning in the porcine heart. Cardiovasc Drugs Ther. 2012;26(2):87–93. https://doi.org/10.1007/s10557-011-6364-y.CrossRefPubMed

40.

Pearce L, Carr RD, Yellon DM, Davidson SM. Nicorandil - an Effective Multitarget Drug for Cardioprotection? Cardiovasc Drugs Ther. 2023;37(1):5–8. https://doi.org/10.1007/s10557-022-07397-x.CrossRefPubMed

41.

Rossello X, Yellon DM. Cardioprotection: The Disconnect Between Bench and Bedside. Circulation. 2016;134(8):574–5. https://doi.org/10.1161/CIRCULATIONAHA.116.022829.CrossRefPubMed

42.

Yano N, Tseng A, Zhao TC, Robbins J, Padbury JF, Tseng YT. Temporally controlled overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility–a new transgenic model. Am J Physiol Heart Circ Physiol. 2008;295(4):H1690–4. https://doi.org/10.1152/ajpheart.00531.2008.CrossRefPubMedPubMedCentral

43.

Fineschi V, Michalodimitrakis M, D’Errico S, et al. Insight into stress-induced cardiomyopathy and sudden cardiac death due to stress. A forensic cardio-pathologist point of view. Forensic Sci Int. 2010;194(1–3):1–8. https://doi.org/10.1016/j.forsciint.2009.10.025.CrossRefPubMed

44.

Piper HM, Abdallah Y, Schafer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res. 2004;61(3):365–71. https://doi.org/10.1016/j.cardiores.2003.12.012.CrossRefPubMed

45.

Jennings RB. Historical perspective on the pathology of myocardial ischemia/reperfusion injury. Circ Res. 2013;113(4):428–38. https://doi.org/10.1161/CIRCRESAHA.113.300987.CrossRefPubMed

46.

Baroldi G. Different types of myocardial necrosis in coronary heart disease: a pathophysiologic review of their functional significance. Am Heart J. 1975;89(6):742–52.CrossRefPubMed

47.

Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. Heart Fail Rev. 2007;12(3–4):181–8. https://doi.org/10.1007/s10741-007-9025-2.CrossRefPubMed

48.

Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J, Agullo L, Cabestrero A. The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia-reperfusion. Cardiovasc Res. 2006;70(2):274–85. https://doi.org/10.1016/j.cardiores.2006.02.011.CrossRefPubMed

49.

Rodrigo GC, Samani NJ. Ischemic preconditioning of the whole heart confers protection on subsequently isolated ventricular myocytes. Am J Physiol Heart Circ Physiol. 2008;294(1):H524–31. https://doi.org/10.1152/ajpheart.00980.2007.CrossRefPubMed

50.

Maxwell MP, Hearse DJ, Yellon DM. Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res. 1987;21(10):737–46. https://doi.org/10.1093/cvr/21.10.737.CrossRefPubMed

51.

Caggiano LR, Holmes JW, Witzenburg CM. Individual variability in animal-specific hemodynamic compensation following myocardial infarction. J Mol Cell Cardiol. 2022;163:156–66. https://doi.org/10.1016/j.yjmcc.2021.10.008.CrossRefPubMed

52.

Flacco N, Segura V, Perez-Aso M, et al. Different beta-adrenoceptor subtypes coupling to cAMP or NO/cGMP pathways: implications in the relaxant response of rat conductance and resistance vessels. Br J Pharmacol. 2013;169(2):413–25. https://doi.org/10.1111/bph.12121.CrossRefPubMedPubMedCentral

53.

Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol. 2010;65(5):565–70. https://doi.org/10.1080/ac.65.5.2056244.CrossRefPubMed

Title: Novel Selective Cardiac Myosin-Targeted Inhibitors Alleviate Myocardial Ischaemia–Reperfusion Injury
Authors: Nur Liyana Mohammed Yusof
Derek M. Yellon
Sean M. Davidson
Publication date: 04-01-2025
Publisher: Springer US
Keyword: Myocardial Infarction
Published in: Cardiovascular Drugs and Therapy
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-024-07663-0

Keynote webinar | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

Keynote webinar | Spotlight on medication adherence

Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan